A Phase I/II study of Pemetrexed plus Erlotinib therapy in Previously Treated Non-Small-Cell Lung Cancer.
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000002900
- Lead Sponsor
- Osaka Univ.Hospital Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1) Patients with idiopathic pulmonary fibrosis, other interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug induced pulmonary damage 2) Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage 3) Patients with infection requiring iv administration of antibiotics and/or antifungal agents 4) Patients unable to be treated with PO drugs 5) Clinically significant eye diseases such as severe dry eye, keratoconjunctivitis 6) Pregnancy, breast feeding and suspected pregnancy 7) Severe bone marrow suppression 8) Symptomatic brain metastasis 9) Active synchronous malignancies 10) Severe renal function disorder (creatinin clearlance less than 45mL/min) 11) Uncontrolled diabetes mellitus 12) Other clinically significant complications 13) Other conditions inadequate for this research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method